Dalrada Financial Corporation said it has appointed Elizabeth Ann Winzeler, Ph.D., a professor in the Department of Pediatrics at the University of California, San Diego (UCSD), School of Medicine, as a member of the advisory board of its Dalrada Health business.
"Dr Winzeler's vast experience in academic and industrial antimicrobial drug discovery will have a positive impact on accelerating Dalrada Health's initiatives in the pharmaceutical market," newly appointed chairman and CEO Brian Bonar said in a statement.
READ: Dalrada brings on Brian McGoff as its new president and COO
Winzeler received a Ph.D. from the Department of Developmental Biology at Stanford University, where she trained under microbiologists and geneticists, before a joint position at the Scripps Research Institute and the Genomics Institute of the Novartis Research Foundation. Her efforts with malaria drug discovery yielded several novel antimalarial chemotypes that are currently in late-stage clinical trials.
At UCSD, she leads a group that uses systematic, data-intensive methods to solve problems at the interface of host-pathogen biology, typically involving large collections of chemical screening data and whole-genome sequencing.
Winzeler has received many accolades throughout her career, including awards from the Keck Foundation, the Ellison Medical Foundation, and the Bill and Melinda Gates Foundation, where she is currently the director of the Foundation's Malaria Drug Accelerator (MalDA).
She is a fellow of the American Academy of Microbiology, and was elected to the National Academy of Medicine this year.
Dalrada is composed of distinguished life sciences industry leaders whose industry knowledge and guidance are intended to accelerate Dalrada Health's national healthcare model.
The company said it envisions a comprehensive healthcare solution with unique offerings that include physicians and clinicians at treatment clinics, eventually expanding into telemedicine, engaging Dalrada-owned testing facilities and laboratories, and utilizing company-specific technologies to facilitate rapid growth of the business.
Dalrada plans on entering the pharmaceutical space with an accelerated strategic plan to leverage its pre-existing capabilities.
Contact the author at jon.hopkins@proactiveinvestors.com